Current and emerging treatments in Parkinson's disease

Annals of the Academy of Medicine Singapore

Volumn 30, Issue 2, 2001, Pages 128-133

  Tan, Adrian K Y ^a  

^a NONE   (Singapore)

Author keywords

COMT inhibitor; Deep brain stimulation; Dopamine agonist; Dyskinesia; Pallidotomy

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROTROPHIC FACTOR; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

AMNESIA; BRAIN DEPTH STIMULATION; CONFERENCE PAPER; CONFUSION; DEGENERATIVE DISEASE; DISABILITY; DYSKINESIA; GENE THERAPY; HUMAN; MOTOR ACTIVITY; NEUROPROTECTION; PALLIDOTOMY; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0034942621     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Kessler I I. Epidemiologic studies of Parkinson's disease: III. A community based survey. Am J Epidemiol 1972; 96:242-4.
2. Duvoisin R, Golbe L I. Toward a definition of Parkinson's disease. Neurology 1989; 39:746.
3. Hughes A J, Daniel S E, Kilford L, Lees A J. Accuracy of the clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-4.
4. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameters: initial therapy of Parkinson's disease [summary statement]. Neurology 1993; 43:1296-7.
5. Parkinson Study Group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328:176-83.
6. rd ed. Baltimore, Md: Williams & Wilkins, 1998:67-104.
7. Lees A J. Comparison of the therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995; 311:1602-7.
8. Olanow C W. Selegiline: current perspectives on issues related to neuroprotection and mortality. Neurology 1996; 47(Suppl 3):S210-6.
9. Olanow C W, Fahn S, Langston J W, Godbold J. Selegiline and mortality in Parkinson's disease. Ann Neurol 1996; 40:841-5.
10. Mentenopoulos G, Katsarous Z, Bostantjopoulous, Logothetis J. Piribedil therapy in Parkinson's disease. Use of the drug in retard form. Clin Neuropharmocol 1989; 12:23-8.
11. Brooks D J, Torjanski N, Burn D J. Ropinorole in the symptomatic treatment of Parkinson's disease. J Neurol Trans 1995; 45(Suppl):231-8.
12. Guttman M and the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997; 49:1060-5.
13. Korczyn M, Brooks D J, Brunt E R, Poewe W H, Rascol O, Stocchi F. Ropinorole vs bromocriptine in the treatment of early Parkinson's disease: a 6 month interim report of a 3-year study. Mov Disord 1998; 13:46-51.
14. Rinne U K. Early cobination of bromocriptine and levodopa in the treatment of Parkinson's disease. A 5-year follow-up. Neurology 1987; 37:826.
15. Rascol O, Brooks D J, Korczyn A D, De Deyn P P, Clarke C E, Lang A E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinorole or levodopa. N Engl J Med 2000; 342:1484-91.
16. Poewe W H, Lees A J, Stern G M. Low dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986; 36:1528-30.
17. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate release and controlled release carbidopa/levodopa in Parkinson's disease. Eur J Neurol 1997; 37:23-7.
18. Agid Y. Levodopa: is toxicity a myth? Neurology 1998; 50:858-63.
19. Kurth M C, Adler C H, Saint Hilaire M, Singer C, Waters C, LeWitt P, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multi-center, double-blind, randomized, placebo-controlled trial. Neurology 1997; 48:81-7.
20. Myllyla W, Jackson M, Larsen J P, Baas H. Tolcapone International Parkinson's Disease Study (TIPS) Group 1. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with 'wearing-off phenomenon: a multicenter, double-blind, randomized, placebo-controlled trial. Eur J Neurol 1997; 4:333-41.
21. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burhard P R. Tolcapone and fulminant hepatitis. Lancet 1998; 352:958.
22. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson' disease patients. Ann Neurol 1997; 42:747-55.
23. Pincus J H, Barry K. Protein redistribution diet restores motor function in patients with dopa-resistant 'off' periods. Neurology 1987; 38:481-3.
24. Papa S M, Chase T N. Levodopa induced dyskinesias improved by a glutamate antogonist in parkinsonian monkeys. Ann Neurol 1996; 39:574-8.
25. Metman L V, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase T N. Amantidine for levodopa-induced dyskinesias. A 1-year follow-up study. Arch Neurol 1999; 56:1383-6.
26. Laitenen L V, Bergenheim A T, Hariz M I. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76:53-61.
27. DeLong M R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13:281-5.
28. Rand R W, Jacques D B, Melbye R W, Copcutt B G, Fischer M R, Levenick M N. Gamma knife thalamotomy and pallidotomy in patients with movement disorders: preliminary results. Stereotact Funct Neurosurg 1993; 61(suppl):65-92.
29. Dogali M, Fazzini E, Kolodny E, Eidelberg D, Sterio D, Devinsky O, et al. Stereotactic ventral pallidotomy for Parkinson' disease. Neurology 1995; 45:753-61.
30. Baron M S, Vitek J L, Bakay R A E, Green J, Kaneoke Y, Hashimoto T, et al. Treatment of advanced Parkinson's disease by posteroventral GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996; 40:355-66.
31. Lang A E, Lozano A M, Montgomery E, Duff J, Tasker R, Hutchison W. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997; 337:1036-42.
32. Siegfried J, Lippitz B. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all Parkinson's symptoms. Neurosurgery 1994; 35:1126-30.
33. Pahwa R, Wilkinson S, Smith D, Lyons K, Miyawaki E, Koller W C. High frequency stimulation of the globus pallidus for the treatment of Parkinson's disease. Neurology 1997; 49:249-53.
34. Krack P, Pollak P, Limousin P, Hoffman D, Benazzous A, Le Bas J F, et al. Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol 1998; 43:180-92.
35. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffna D, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339:1105-11.
36. Kumar R, Lozano A M, Kim Y J, Hutchison W D, Sime E, Halket E, et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 1998; 51:850-5.
37. Fazzini E, Dogali M, Beric A, Eidelberd D, Sterio D, Gianutos J, et al. The effects of unilateral ventral posterior medial pallidotomy in patients with Parkinson's disease and Parkinson's plus syndromes. In: Koller W C, Paulson G, editors. Therapy of Parkinson's Disease. New York: Marcel Dekker, 1994:353-79.
38. Freeman T B, Olanow C W, Hauser R A, Nauert G M, Smith D A, Borlongan C V, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995; 38:379-88.
39. Lindvall O, Sawle G, Widner H, Rothwell J C, Bjorklund A, Brooks D, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35:172-80.
40. Kordower J H, Freeman T B, Snow B J, Vingerhoets F J, Mufson E J, Sanberg P R, et al. Neuropathological evidence of graft survival and striatal reinnervation after transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332:1118-24.
41. Miyoshi Y, Zhang Z, Ovadia A, Lapchak P A, Collins F, Hilt D, et al. Glial cell line-derived neurotrophic factor interactions and reduction of side effects in parkinsonian monkeys. Ann Neurol 1997; 42:208-14.